Development of Your MS Questionnaire: A Patient-completed Digital Tool to Monitor Multiple Sclerosis Disease Symptoms and Their Impact on People’s Life

Gavin Giovannoni1, Enrique Alvarez2, Olaf Hoffmann3, Celia Oreja-Guevara4, Patrick Vermersch5, Mudeer Khwaja6, Bianca Stadler7, Jo Vandercappellen6, Tjalf Ziemssen8

1Bizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; 2University of Colorado School of Medicine, Aurora, CO, USA; 3Department of Neurology, Alexander St. Josers Hospital, Potsdam, Germany; 4Multiple Sclerosis Center at the University Hospital San Carlos, Madrid, Spain; 5Univ. Lille, Inserm UMR U1172 LILNeCog, CHU Lille, FVU Precise, Lille, France; 4Novartis Pharma AG, Basel, Switzerland; 6Novartis Pharma GmbH, NURNBERG, Germany; 7Department of Neurology, University Clinic Carl-Gustav Carus, Dresden, Germany

Introduction

- Your Multiple Sclerosis Questionnaire (YMSQ; www.yourms.com) is a patient-completed digital tool to capture their perceptions of changes in multiple sclerosis (MS) symptoms, disability progression and impact on daily living over the past 6 months
- A tool to facilitate conversations between physicians and patients who was identified as an unmet need during the development and validation of MSProDiscussTM, a physician-completed tool1
- Insight gathering from people living with MS (PlwMS) aimed to improve the YMSQ were carried out based on the key suggestions from PlwMS and patient councils

Objective

To describe the steps involved in the development of the YMSQ, particularly feedback from PwMS

Methods

Overview of stages of YMSQ development (Fig. 1)

1. Content development
2. Design of YMSQ
3. Final cognitive debriefing
4. Interviews
5. Refinement of YMSQ

Final cognitive debriefing

- Two rounds of telephonic interviews with patients aged ≥18 years and diagnosed with relapsing-remitting MS or secondary progressive MS were conducted by trained and qualified interviewers

Patient councils/advisory board meetings

- Participants provided general feedback on the draft tool, potential improvements and recommendations for changes to the YMSQ

Results

Outcomes of cognitive debriefing

- Key changes in the questionnaire following patient feedback are presented in Fig. 2

Conclusions

- Improvements to the YMSQ were carried out based on the key suggestions from PwMS and patient councils
- PwMS and patient councils were positive about the applicability of YMSQ in enhancing and structuring the conversation between PwMS and their HCPs and as a disease monitoring tool in clinical practice
- YMSQ has been also tested for usability and usefulness with HCPs and is freely available at https://www.yourms.com

References

Acknowledgements

Disclosures

Jo Vandercappellen, Mudeer Khwaja, Bianca Stadler are employees of Novartis. Gavin Giovannoni is a steering committee member on the declinurab trials for AbbVie, the BGG2 and declinurab-trials for Biogen, the fingolimod and approved trials for Novartis, the leflunomide trial for Teva and the contributed trials for Roche. He has also received consulting fees for advisory board meetings for oral clinical trials for Merck-KGA, Sanofi-Gencryse, and in relation to Gobb activities for Synthon BV, as well as honoraria for speaking at the Physicians’ Summit and several medical education meetings. He is also the Co-Chief Editor of Multiple Sclerosis and Related Disorders (Elsevier). Enrique Alvarez received compensation for consulting from Actellion/Janssen, Alexion, Bayer, Biogen, Celgene/IMS, ENO Seros/Merc, Genentech/Roche, Gencryse, Novartis, Sanofi, and TG Therapeutics, and for research from Biogen, Genentech/Roche, Novartis, TG Therapeutics. Patient Centered Outcome Research Initiative, National Multiple Sclerosis Society, National Institute of Health, and Rocky Mountain MS Center. Olaf Hoffmann received consulting fees from Biogen, Merck, Meriva, Novartis, Roche, and Sanofi; compensation for research from Biogen, Meriva, Novartis, and Sanofi; and as a speaker from Merck, Novartis, Roche, and Sanofi. Celia Oreja-Guevara received consulting fees from Novartis, Alexion, and Roche; compensation for research from Alexion; and as a speaker from Novartis and Roche. Patrick Vermersch has received compensation for consulting and/or research and replication, travel, and accommodation for meetings from Biogen, Novartis, Sanofi, Teva, Meriva, and Celgene. Tjalf Ziemssen has received compensation for consulting and lecture from Alelixion, Biogen, Celgene, Novartis, Pfizer, and Sanofi and research support from Novartis, Biogen, Roche, Sanofi, and Teva and for research from Biogen, Novartis, Roche, Teva, and Sanofi.
